Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sipuleucel-T (APC8015) for prostate cancer.

Rosendo So-Rosillo1, Eric J Small

  • 1Hematology/Oncology, University of California, 505 Parnassus Avenue, M1286 San Francisco, CA 94143-1270, USA. rsorosillo@hemeonc.ucsf.edu

Expert Review of Anticancer Therapy
|October 6, 2006
PubMed
Summary

Sipuleucel-T immunotherapy shows promise in treating prostate cancer by improving overall survival in men with metastatic disease. Further trials are exploring its use in various prostate cancer stages and combinations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Genome biology·2026
Same author

Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.

Cancer·2025
Same author

A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.

Nature communications·2025
Same author

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer.

Nature genetics·2025
Same author

Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.

JNCI cancer spectrum·2025

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Sipuleucel-T (APC8015) is an autologous cellular immunotherapy product.
  • It utilizes dendritic cells pulsed with a fusion protein (PA2024) targeting prostatic acid phosphatase.

Purpose of the Study:

  • To evaluate the efficacy of Sipuleucel-T in prostate cancer.
  • To assess its impact on prostate-specific antigen levels and survival outcomes.

Main Methods:

  • Phase II and III clinical trials were conducted in men with prostate cancer.
  • Participants included those with biochemically relapsed, hormone-refractory, and metastatic hormone-refractory disease.

Main Results:

  • Phase II trials showed decreased PSA and prolonged PSA doubling time in relapsed prostate cancer.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jul 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

  • Phase III trials demonstrated improved median overall survival in asymptomatic metastatic hormone-refractory prostate cancer patients compared to placebo.

    • Conclusions:

    • Sipuleucel-T exhibits biological activity and clinical response in hormone-refractory prostate cancer.
    • It offers a survival benefit for men with asymptomatic, metastatic hormone-refractory prostate cancer.
    • Ongoing trials investigate Sipuleucel-T in diverse prostate cancer settings and combination therapies.